The implementation of immune checkpoint inhibitors to the oncology clinic signified a new era in cancer treatment. After the first indication of melanoma, an increasing list of additional cancer types are now treated with immune system targeting antibodies to PD-1, PD-L1 and CTLA-4, alleviating inhibition signals on T cells. Recently, we published proof-of-concept results on a novel checkpoint inhibitor, NKG2A. This receptor is expressed on cytotoxic lymphocytes, including NK cells and subsets of activated CD8+ T cells. Blocking antibodies to NKG2A unleashed the reactivity of these effector cells resulting in tumor control in multiple mouse models and an early clinical trial. Monalizumab is inhibiting this checkpoint in human beings and future clinical trials will have to reveal its potency in combination with other cancer treatment options.
Keywords: CD8 T cells; Cancer immunotherapy; HLA-E/Qa-1; Inhibitory immune receptor; NK cells; NKG2A.
Conflict of interest statement
P.A., R.Z. and E. V are employees of Innate-Pharma. The other authors declare no competing financial interests.
Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK Cells.Cell. 2018 Dec 13;175(7):1731-1743.e13. doi: 10.1016/j.cell.2018.10.014. Epub 2018 Nov 29. Cell. 2018. PMID: 30503213 Free PMC article. Review.
The NKG2A - HLA-E axis as a novel checkpoint in the tumor microenvironment.Clin Cancer Res. 2020 May 14:clincanres.2095.2020. doi: 10.1158/1078-0432.CCR-19-2095. Online ahead of print. Clin Cancer Res. 2020. PMID: 32409305
Innate immunity in COVID-19 patients mediated by NKG2A receptors, and potential treatment using Monalizumab, Cholroquine, and antiviral agents.Med Hypotheses. 2020 Apr 22;140:109777. doi: 10.1016/j.mehy.2020.109777. Online ahead of print. Med Hypotheses. 2020. PMID: 32344314 Free PMC article.
NKG2A Blockade Potentiates CD8 T Cell Immunity Induced by Cancer Vaccines.Cell. 2018 Dec 13;175(7):1744-1755.e15. doi: 10.1016/j.cell.2018.10.028. Epub 2018 Nov 29. Cell. 2018. PMID: 30503208 Free PMC article.
The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.Clin Ther. 2015 Apr 1;37(4):764-82. doi: 10.1016/j.clinthera.2015.02.018. Epub 2015 Mar 29. Clin Ther. 2015. PMID: 25823918 Free PMC article. Review.
Cited by 1 article
NKG2A and COVID-19: another brick in the wall.Cell Mol Immunol. 2020 Jun;17(6):672-674. doi: 10.1038/s41423-020-0450-7. Epub 2020 May 7. Cell Mol Immunol. 2020. PMID: 32382127 Free PMC article. No abstract available.